Polarized Reflectance Spectroscopy for Oral Lesions (PolProbe)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01604759|
Recruitment Status : Completed
First Posted : May 24, 2012
Last Update Posted : January 31, 2017
In this study the investigators are conducting research to determine whether a new optical device using polarization reflectance spectroscopy can help doctors or dentists identify abnormalities in the mouth that require follow-up. To establish this, measurements are needed from a large number of individuals with different abnormalities in their mouth.
The investigators believe the proposed approach has potential to improve and enable mass screening for precancerous and early cancers of the oral cavity by improving the predictive value of oral cavity exams, particularly for less experienced practitioners.
The information from this study will be compared to results from the pathology report of the tissue taken from your mouth.
- Polarized reflectance spectroscopy can distinguish high-risk oral lesion from normal and reactive oral lesions.
- Polarized reflectance spectroscopy can capture low-grade oral lesions that have characteristics associated with a high risk of progression to cancer.
|Condition or disease||Intervention/treatment||Phase|
|Oral Cancer||Device: Polarized Reflectance Spectroscopy System||Phase 1|
The clinician will place a fiber-optic probe designed to measure the polarized reflectance spectra over the visible optical region on a site of interest in the subject's mouth, including lesional mucosa, normal adjacent and contralateral mucosa. The site for placement of the probe will be determined by the examiner, an experienced Oral Pathologist. The probe examination will take no more than 15 minutes in addition to the subject's appointment time for their routine visits.
A 4um unstained tissue section from surgery or biopsy, part of their scheduled care, will be requested for quantitative histological analysis. The morphometric parameters obtained from polarized reflectance measurements will be compared with the histology and quantitative pathology (nuclear phenotype score) from the tissue sections from the lesion. The collected spectra data from normal looking areas from adjacent normal looking mucosa and contralateral mucosa will be used to determine patient to patient variation in the polarized reflectance of oral mucosa.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Polarized probe measurement.
All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
Device: Polarized Reflectance Spectroscopy System
Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
- To use the spectroscopic data collected to create a model for normal, dysplastic and cancerous tissue. [ Time Frame: 2 years ]The goals of the statistical analysis will be to determine an appropriate model for predicting whether the lesion is normal or abnormal (dysplasia or carcinoma) based on spectroscopic characteristics. The investigators will estimate sensitivity and specificity of the predictions made by the model and compare this to sensitivity and specificity of standard white light clinical examination currently used in clinical practice.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01604759
|Canada, British Columbia|
|British Columbia Cancer Agency - Vancouver Centre|
|Vancouver, British Columbia, Canada, V5Z 1L3|
|Principal Investigator:||Catherine Poh, M.D. Ph.D||British Columbia Cancer Agency|